The investigation of haematological malignancies (cancers of the blood, bone marrow and lymph nodes) represents a significant area of clinical and research activity. Our understanding of how and why blood cancers develop is underpinned by basic research into how blood cells develop normally and what happens at the earliest stage of malignancy. Research is closely aligned with clinical treatment so that patients receive the best diagnostic and therapeutic options based on their particular cancer.
Leukemia trial – JAK2
This trial identified a single point mutation in JAK2 in many patients with myeloproliferative neoplasms, and validated a molecular diagnostic test, which is the first screening test to be introduced worldwide.
A trial testing new drug combinations
A large clinical trial of over 1,000 patients with a myeloproliferative disorder called essential thrombocythaemia is taking place to assess the efficiency of different combinations of drug treatment.
Integrating the lab and the clinic
Myeloproliferative disorders are a group of diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets. Researchers have discovered that many people with these disorders have a particular genetic mutation affecting an enzyme, called JAK2. This enzyme has an important role for carrying messages within cells but, in the case of these disorders, the mutation causes too many new blood cells to be produced. The finding means that patients can be offered different treatment depending on whether or not their disease has been caused by the mutation.
Current open trials in Cambridge
The table below lists current open trials for MPN cancer coordinated by the Cambridge Cancer Trials Centre (last updated January 2016).
|Trial name||Trial description||Contact|
|MAJIC||A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide||Dr Anna Godfrey|
|The Causes of Clonal Blood Cell Disorders||The Causes of Clonal Blood Cell Disorders||Prof Tony Green|
The table below lists current open trials for haematological cancer coordinated by the Cambridge Cancer Trials Centre (last updated January 2016).
|Trial name||Trial description||Contact|
AML19 will build upon the results of previous trials in acute myeloid leukaemia. It will evaluate several relevant therapeutic questions in patients who are 18-60 years old and suitable for intensive chemotherapy. For patients who do not have the APL subtype, the investigators will evaluate the best way of adding mylotarg to induction chemotherapy.
|Dr Jenny Craig|
The AML18 Trial will evaluate several therapeutic questions in Acute Myleoid Leukaemia (AML). The trial will recruit 1600 patients primarily over the age of 60 who are considered fit for an intensive approach to treatment.
|Dr Jenny Craig|
|CANC - 3935 VELCADE Melphalan-Prednisone (VMP) vs Daratumumab with VMP (D-VMP) in Myeloma||A Phase 3, Randomised, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy||Dr Charles Crawley|
|CANC - 3948 SADAL||A Phase 2b Openlabel, Randomized Two-arm Study of Selinexor (KPT330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||Dr George Follows|
|Figaro||A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation||Dr Charles Crawley|
|FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab||Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab||Dr George Follows|
|I-BET||A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies||Dr Brian Huntly|
|LI-1||Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial||Dr Jenny Craig|
|MDS REGISTRY||A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes.||Dr Jenny Craig|
|MUK five||A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma.||Dr Charles Crawley|
|NCRN508 ECHELON-2 - brentuximab vedotin and CHP (A+CHP) VS CHOP in T-cell lymphomas||A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas||Dr Ben Uttenthal|
|NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC)||A phase 3, multicenter, randomized, doubleblind study to compare the efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to ipss lower-risk myelodysplastic syndromes||Dr Theodora Foukaneli|
|PACIFICO||Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO)||Dr George Follows|
|PROmPT Platelet Responsiveness and Outcome from Platelet Transfusion||PROmPT Platelet Responsiveness and Outcome from Platelet Transfusion Does inherent variation in donor platelet function affect the clinical efficacy of apheresis platelets? A randomised double blind single centre trial||Dr Theodora Foukaneli|
|ProT4 (Prophylactic Transfer of CD4 Lymphocytes)||Multicentre randomised phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for indolent non-Hodgkin's lymphoma and CLL||Dr Charles Crawley|
Stem cell transplantation has been used for many years in the treatment of cancers that affect the blood, bone marrow and lymphatic system. Most transplants use blood forming cells (‘stem cells’). If the patient’s own cells are infused, this is called an ‘autologous transplant’, and if cells are from another person, this is called an ‘allogeneic transplant’.
The primary aim of the trial is to improve survival at one year post transplant, but the study will also look at the side effects of the transplants and quality of life.
|Dr Ben Uttenthal|
|UKALL 14||A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia||Dr Jenny Craig|
|UKALL 2011||United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011||Dr Michael Gattens|
|Understanding and managing the coagulopathy of APL (Pilot Study)||Understanding and managing the coagulopathy of Acute Promyelocytic leukaemia in the acute stage - pilot study.||Dr Jenny Craig|
If you would like further information about how to take part in any of the clinical trials listed here that are open to recruitment, please talk to your cancer specialist as patients usually need to be referred by their doctor.